You are receiving this email because you are or were a
BreakoutWatch.com subscriber, or have subscribed to our weekly
newsletter.
To read this newsletter on the site, click here: Newsletter
.
The S&P 500 Index recorded its strongest weekly gain in nearly a year, as signs of a slowing economy and a policy statement from the Federal Reserve that was generally perceived as dovish led to a sharp decrease in long-term bond yields. Growth stocks and the technology-heavy Nasdaq Composite Index outperformed somewhat, but the gains were broad-based and led by the small-cap Russell 2000 Index, which scored its best weekly gain since October 2022. [more...]
Dow Jones | |
---|---|
Last Close | 34061.3 |
Wk. Gain | 4.68 % |
Yr. Gain | 2.75 % |
Trend | Up |
S&P 500 | |
---|---|
Last Close | 4358.34 |
Wk. Gain | 5.29 % |
Yr. Gain | 13.12 % |
Trend | Down |
NASDAQ Comp. | |
---|---|
Last Close | 13478.3 |
Wk. Gain | 5.71 % |
Yr. Gain | 27.61 % |
Trend | Down |
Russell 2000 | |
---|---|
Last Close | 1760.7 |
Wk. Gain | 6.95 % |
Yr. Gain | -0.53 % |
Trend | Down |
Sector | Wk. Change % | Yr. Change % | Trend |
---|---|---|---|
Consumer Discretionary | 6.63 | 24.1 | Up |
Consumer Staples | 2.89 | -5.15 | Up |
Energy | 2.27 | 2.02 | Down |
Finance | 6.89 | -0.79 | Up |
Health Care | 3.11 | -6.52 | Down |
Industrials | 5.07 | 6.66 | Down |
Technology | 6.07 | 35.3 | Down |
Materials | 4.41 | 1.29 | Up |
REIT | 8.24 | -5.93 | Up |
Telecom | 6.96 | 33.73 | Down |
Utilities | 5.02 | -13.74 | Up |
Watchlist | Symbol | Company | Industry | C Score* | % Gain |
---|---|---|---|---|---|
SQZ | ICPT | Intercept Pharmaceuticals, Inc. | Biotechnology | 86.2 % | 0.1 % |
SQZ | MNSO | MINISO Group Holding Limi | Specialty Retail | 80.2 % | 3.4 % |
SQZ | GBDC | Golub Capital BDC, Inc. | Asset Management | 79.9 % | 2.6 % |
CWH | QLYS | Qualys, Inc. | Software - Infrastructure | 79.7 % | 3 % |
CWH | CXW | CoreCivic, Inc. | Specialty Industrial Machinery | 77.3 % | 3 % |
SQZ | LI | Li Auto Inc. | Auto Manufacturers | 76.9 % | 3.9 % |
CWH | PSN | Parsons Corporation | Information Technology Services | 76.6 % | 4.7 % |
CWH | EQT | EQT Corporation | Asset Management | 76.1 % | 0.1 % |
CWH | VRTX | Vertex Pharmaceuticals Inco | Biotechnology | 75.9 % | 0.1 % |
SQZ | OLLI | N/A | Discount Stores | 75.9 % | 3.3 % |
SQZ | TJX | TJX Companies, Inc. | Apparel Retail | 75.9 % | 1.2 % |
SQZ | LEU | Centrus Energy Corp. Class A | Uranium | 75.7 % | 0.6 % |
SQZ | COKE | Coca-Cola Consolidated, Inc. | Beverages - Non-Alcoholic | 75 % | 1.9 % |
DB | DKNG | DraftKings Inc. | Gambling | 74.9 % | 3.4 % |
DB | TM | Toyota Motor Corporation | Auto Manufacturers | 74.8 % | 3.6 % |
SQZ | SPOK | Spok Holdings, Inc. | Health Information Services | 74.7 % | 2.5 % |
SQZ | LIN | Linde plc Ordinary Shares | Specialty Chemicals | 74.5 % | 3.6 % |
CWH | VIV | Telefonica Brasil S.A. American Depositary Shares | Telecom Services | 74.2 % | 3.6 % |
CWH | TIMB | TIM S.A. American Depositary Shares (Each represen | Telecom Services | 73.7 % | 4 % |
DB | MSI | Motorola Solutions, Inc. | Communication Equipment | 73.6 % | 1.5 % |
*C score is our assessment of a Stock's correlation to CAN SLIM principles. It combines a stock's Technical and Fundamental merits and is expressed as a percentage. |
Watchlist | Symbol | Company | Industry | C Score* | % Loss |
---|---|---|---|---|---|
SS | SXC | SunCoke Energy, Inc. | Coking Coal | 66.4 % | -3.2 % |
SS | ZEUS | Olympic Steel, Inc. | Steel | 61.6 % | -1.5 % |
*C score is our assessment of a Stock's correlation to CAN SLIM principles. It combines a stock's Technical and Fundamental merits and is expressed as a percentage. |
Symbol | BoP | Company | Industry | Within x% of BoP | C Score* |
---|---|---|---|---|---|
USAP | 0 | Riley Exploration Permian, Inc. | Biotechnology | 75.4 | |
MANH | 79.2 | ||||
OWL | 76.1 | ||||
ARLP | 74.5 | ||||
*C score is our assessment of a Stock's correlation to CAN SLIM principles. It combines a stock's Technical and Fundamental merits and is expressed as a percentage. |
Aug. 16, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the achievement of First-Patient-In for the company-sponsored Phase 2 clinical trial evaluating darovasertib as neoadjuvant and adjuvant therapy in primary uveal melanoma (UM) patients.